Skip to Content

Applied Genetic Technologies Corporation

Merger

  • Date:
  • 10/24/2022
  • Company Name:
  • Applied Genetic Technologies Corporation
  • Stock Symbol:
  • AGTC
  • Company Name - Buyer:
  • Syncona Limited
  • Stock Symbol - Buyer:
  • SYNC
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/23/2022

Case Finder

Locate any case using the tools below.

NEW YORK, October 24, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Applied Genetic Technologies Corporation (NASNAQ: AGTC) (“AGTC”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Syncona Limited (LON: SYNC) (“Syncona Limited”).

On October 23, 2022, AGTC announced that it had entered into an agreement to be acquired by Syncona Limited in a cash and CVR deal. Pursuant to the merger agreement, an indirect subsidiary of Syncona Limited will initiate a tender offer to acquire all outstanding shares of AGTC common stock. The upfront cash consideration in the transaction will consist of $0.34 per share of AGTC common stock (including common stock underlying restricted stock units and in-the-money stock options). AGTC equity holders will also receive in the transaction, for each share of AGTC common stock, one non-tradeable CVR. The holders of the CVRs will be entitled to receive payments of up to an additional $50.0 million in the aggregate upon the achievement of certain milestones related to transactions involving AGTC’s assets and regulatory and commercial milestones related to AGTC’s products. The deal is expected to close in the fourth quarter of 2022.

Bragar Eagel & Squire is concerned that AGTC’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for AGTC’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Applied Genetic Technologies Corporation. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: